ETS2 and colorectal carcinoma: In addition, the ETS2 level was significantly higher in CRC patients with low mutation burden and low microsatellite instability (Supplementary Fig. 1–2), suggesting that ETS2 might be misregulated by non-genetic pathways in CRC.